Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (538)	3/7/2005 2:45:57 PM
From: zeta1961	Read Replies (1) \| Respond to of 946

taxol equivalent without hair loss many not be an economically compelling option. Upon what are you basing this conclusion? Disclosure: Sold all my CTIC today because of Bianco's history which unfortunately repeated today..but still care about a successful alternative to Taxol..whether it's Xyotax, or any other molecule.. Zeta

To: former_pgs who wrote (538)	3/7/2005 2:47:06 PM
From: Icebrg	Read Replies (2) \| Respond to of 946

It is not only a matter of alopecia. Not being based on Cremafore is another advantage. Less pain, cardiac side-effects (?) and neurotoxicities a third. Clearly, these patients deserve a "milder" type of chemotherapy if such a thing is available, costs notwithstanding. Seeing FDA approve Abraxane on what appeared to be even flimsier support from its registration trial means that eventually an approval should not be ruled out, as long as CTIC is somehow able to make the argument for non-inferiority stick. Erik